Physician profile
David Strout
NPI 1235433426
$5,976.00
in general payments reported to CMS, 2019-2025
31 companies · $809 in 2025
The $809 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $936 · 2022: $2,040 · 2023: $1,282 · 2024: $909 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,000.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,154.99 | 2021-2025 | Watchman Flx, Watchman Access System, Rhythmia Mapping System |
| Amgen INC. | $777.64 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $678.17 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $360.12 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $298.93 | 2022-2025 | Assure Wcd |
| Abbott Laboratories | $278.43 | 2021-2022 | |
| Pfizer INC. | $266.45 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $262.90 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.59 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $231.67 | 2022-2024 | Opsumit |
| Merck Sharp & Dohme LLC | $206.63 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $156.58 | 2021-2024 | Nexletol |
| Edwards Lifesciences Corporation | $132.12 | 2021 | |
| Biosense Webster, INC. | $123.96 | 2024 | Carto 3 |
| Cvrx, INC. | $115.94 | 2025 | Barostim Neo System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $82.10 | 2021-2022 | |
| Novo Nordisk INC | $73.95 | 2024-2025 | Ozempic, Wegovy |
| Biotronik INC. | $66.65 | 2021-2022 | |
| Chiesi USA, INC. | $53.56 | 2021-2023 | Kengreal, Cleviprex |
| Scpharmaceuticals INC. | $44.99 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $43.46 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $42.21 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $40.09 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $34.46 | 2021-2022 | |
| Penumbra, INC. | $34.26 | 2023 | Indigo System |
| Amarin Pharma, INC. | $32.59 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.08 | 2024 | |
| Alnylam Pharmaceuticals INC. | $29.47 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $28.85 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $26.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Strout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.